Actively Recruiting
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Led by The First People's Hospital of Lianyungang · Updated on 2024-06-26
46
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
CONDITIONS
Official Title
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily agree to participate and sign informed consent with good compliance
- Histologically or pathologically confirmed EGFR wild-type or EGFR mutant NSCLC resistant to treatment
- Have 5 or fewer brain metastases with at least one assessable lesion on imaging (RECIST 1.1)
- Age between 18 and 80 years
- ECOG performance status of 0 or 1 with expected survival of at least 3 months
- Able to take concurrent oral anlotinib during radiotherapy regardless of prior treatments
- Good major organ function with laboratory values meeting specified hematological, biochemical, and coagulation criteria
You will not qualify if you...
- Squamous cell carcinoma or adenosquamous carcinoma with cavitary lung cancer or recent significant hemoptysis
- Diffuse pleural metastases, malignant pericardial effusion, or diffuse spinal cord involvement
- History of other malignancies within 5 years except certain cured skin or cervical conditions
- Current pulmonary pneumonia of grade 2 or higher
- Conditions affecting oral medication intake such as dysphagia or intestinal obstruction
- Active bleeding or unexplained persistent low hemoglobin
- Recent serious bleeding events or use of anticoagulants beyond allowed low doses
- Unhealed wounds, active ulcers, or recent major surgeries
- Recent use of certain traditional Chinese or immune modulating drugs
- History of organ or blood system transplantation
- Active diverticulitis, abdominal abscess, or gastrointestinal obstruction
- Severe or uncontrolled diseases including poorly controlled blood pressure, recent thrombotic events, severe infections, significant liver disease, positive HIV or syphilis tests, poorly controlled diabetes, or significant proteinuria
- Other serious illnesses or factors that may lead to study termination as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China, 222002
Actively Recruiting
Research Team
X
Xiaodong Jiang, Doc
CONTACT
X
Xiaodong Jiang, Doc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here